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Abstract: Ubiquitination is one of the main post-translational modification of proteins. It plays
key roles in a broad range of cellular functions, including protein degradation, protein interactions,
and subcellular location. In the ubiquitination system, different proteins are involved and their
dysregulation can lead to various human diseases, including cancers. By using data available from
the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases, we here
show that the ubiquitin conjugating enzyme, E2C (UBE2C), is overexpressed in all 27 cancers we
investigated. UBE2C expression is significantly higher in late-stage tumors, which might indicate
its involvement in tumor progression and invasion. This study also revealed that patients with
higher UBE2C levels showed a shorter overall survival (OS) time and worse OS prognosis. Moreover,
our data show that UBE2C higher-expression leads to worse disease-free survival prognosis (DFS),
indicating that UBE2C overexpression correlates with poor clinical outcomes. We also identified
genes with positive correlations with UBE2C in several cancers. We found a number of poorly studied
genes (family with sequence similarity 72-member D, FAM72D; meiotic nuclear divisions 1, MND1;
mitochondrial fission regulator 2, MTFR2; and POC1 centriolar protein A, POC1A) whose expression
correlates with UBE2C. These genes might be considered as new targets for cancers therapies since
they showed overexpression in several cancers and correlate with worse OS prognosis.
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1. Introduction
Most proteins post-translational modifications are essential for proper cellular localization,
substrate activity, and associations with other proteins. One evolutionarily conserved modification
is ubiquitination, which can involve one or multiple defined lysine (K) residues or the N-terminal
methionine residue (M1) [1–3].
Ubiquitin, a highly conserved regulatory protein (76 amino acids), plays an essential role
in modulating protein functions. Ubiquitination is a post-translational modification mediated by
a multi-step process which involves three different enzymes, including E1 ubiquitin-activating
enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin-ligating enzymes. This function leads
to the proteasomal elimination of its substrate or alteration of the substrate activity, localization,
and associations with other partners in its protein networks [2,4,5].
In the ubiquitin-proteasome pathway, anaphase promoting complex/cyclosome (APC/C) and the
ubiquitin conjugating enzyme, E2C (UBE2C), are involved in the initiation of ubiquitin chain formation on
APC/C substrates. UBE2C principally create Lys-11 (K11)-linked polyubiquitination on these substrates
and then APC/C and another E2 enzyme, UBE2S, elongates and branches the ubiquitin, making more
efficient proteolytic degradation signals (i.e., on mitotic cyclins) for the proteasome receptor, S5A, regulating
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mitosis progression. Various cellular processes are regulated by the ubiquitin system; therefore, it is
expected its dysregulation results in human diseases, including cancers [6,7]. UBE2C overexpression has
been found in different human cancers, including hepatocellular carcinoma [8], thyroid [9], colon [10],
breast [11], lung [12], brain [13], and cervical cancer [14].
It has been shown that UBE2C overexpression leads to chromosomes mis-segregation and alters
the cell cycle process, facilitating cell proliferation [15,16]. Moreover, it has also been reported that
UBE2C overexpression correlates with tumor progression and poor prognosis in many tumors [9,16–19].
In this study, the expression levels of UBE2C were evaluated in 27 different cancers using data from the
Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases. We provide
evidences that UBE2C acts as a proto-oncogene and can be considered as a therapeutic target for most
cancers. Our results indicate that UBE2C is overexpressed in 27 studied cancers and its overexpression
correlates worsen the overall survival (OS), suggesting its involvement in tumor progression and
invasion. Our study also identified a number of genes that are in the UBE2C regulatory network.
2. Results
2.1. UBE2C Overexpression in Tumors, Their Pathological Stages, and Subtypes
Data extracted from TCGA database revealed that UBE2C expression was notably higher in
all 27 tumor types compared to matched TCGA normal tissues and GTEx data (Figure 1). We next
assessed the expression of UBE2C in normal tissue using RNA-sequencing data available from GTEx
data. In particular, we compared expression levels of UBE2C between tumors with respect to normal
matches, and data of GTEx. We found that UBE2C showed increased levels in all these cancers with
respect to its expression in the normal tissues. The significant differences between all tumors and
normal samples as a boxplot are given individually in Supplementary data Figure S1.
We next assessed the expression levels of UBE2C with respect to the molecular and histological
subtypes of tumors, tumor grades, and other patient conditions when data are available using UALCAN.
In urologic cancers, we found that histological subtypes of BLCA show increased expression
in both papillary and non-papillary tumors compared to normal (Table 1 and Figure S2 panel 1A).
In relation to its molecular subtype, all reveal upregulated compared to normal with more statistically
significant values for luminal papillary, followed by basal squamous (Table 1 and Figure S2 panel 1B).
In renal cancers, KIRC shows increased expression levels of UBE2C in all grades compared to normal,
with more significant for grade 2, followed by grade 3 and 4 (Table 1 and Figure S2 panel 1C). For its
subtypes, both clear cell type A (ccA) and B (ccB) (p-value < 10−8) subtypes show higher expression
compared to normal, with slightly more significant for ccB (Table 1 and Figure S2 panel 1D). In KIRP
tumors, all histological tumor subtypes showed UBE2C overexpression with high significance for type1
papillary renal cell carcinoma (RCC), followed by type2 papillary RCC (Table 1 and Figure S2 panel 1E).
In PRAD tumors, the increase was statistically more significant for Gleason score 8, followed by Gleason
score 9 and Gleason score 7 (Table 1 and Figure S2 panel 1F). The more statistically significant molecular
signature was observed for erythroblast transformation-specific (ETS) transcription factor ERG (ERG)
fusion, speckle type BTB/POZ protein (SPOP) mutation, and ETS translocation variant 1 (ETV1) fusion
(Table 1 and Figure S2 panel 1G). In relation to the expression of UBE2C in metastatic PRAD based on
androgen receptor (AR) amplification and ERG fusion, there is no significance difference compared to
condition without these changes (Table 1 and Figure S2 panel 1H).
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Compared to normal tissues in BRCA tumors, the expression of UBE2C was higher in all different
subtypes, including triple negative breast cancer (TNBC), HER2-amplification, and luminal subtype
(Table 1 and Figure S2 panel 2A). For its TNBC types, the statistically significant changes were seen
in TNBC-mesenchymal (M), followed by TNBC-immunomodulatory (IM), TNBC-basal-like2 (BL2,),
and TNBC-basal-like1 (BL1; Table 1 and Figure S2 panel 2B). The UBE2C expression in this BRCA was
increased in all pre-, peri-, and post-menopause conditions compared to the normal tissue, but not
significant compared to each other (Table 1 and Figure S2 panel 2C). In addition, UBE2C expression in
BRCA showed high levels in all histological subtypes, with the most significant increase in infiltrating
lobular carcinoma (ILC) and infiltrating ductal carcinoma (IDC; Table 1 and Figure S2 panel 2D).
The expression of amplified MYC proto-oncogene (MYC), cyclin D1 (CCND1), and Erb-B2 receptor
tyrosine kinase 2 (ERBB2) in metastatic breast cancer compared to conditions without amplification
indicated no significant correlation with UBE2C expression (Table 1 and Figure S2 panel 2E).
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Figure 1. UBE2C expression in cancers. Expres ion level of UBE2C acros 27 TC tu r c to
TCGA normal and GTEx data using GEPIA (Gene Expression Profili g Interactive Analysis) webserver.
It is clea that in all 27 c ncers there is notable upregulation of this gene. For ach TCGA tumor
(red), its matched normal and GTEx data (green) are given; T: tumor; N: normal; : number. Y
axis: transcript per million (log2(TPM + 1)). axis: nu ber of tumor and normal samples. ACC:
adrenocortical carcinoma; BLCA: bladder urothelial carcino a; BRCA: breast invasive carcinoma;
COAD: colon adenocarcinoma; DLBC: lymphoid neoplasm diffuse large B-cell lymphoma; ESCA:
esophageal carcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma;
KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell
carcinoma; LAML: acute myeloid leukemia; LGG: brain lower grade glioma; LIHC: liver hepatocellular
carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; OV: ovarian serous
cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PRAD: prostate adenocarcinoma; READ:
rectum adenocarcinoma; SKCM: skin cutaneous melanoma; STAD: stomach adenocarcinoma; TGCT:
testicular germ cell tumors; THCA: thyroid carcinoma; THYM: thymoma; UCEC: uterine corpus
endometrial carcinoma; UCS: uterine carcinosarcoma.
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Table 1. Statistically significant UBE2C overexpression based on histological, molecular subtypes, and different patient statuses (only findings with p-value < 0.05 are given).
Tumor Histological Subtypes Molecular Subtypes Tumor Grade Other Patient Conditions
BLCA N-vs.-Papillary tumors: p < 10
−12
N-vs.-NonPapillary tumors: p < 10−12
N-vs.-Neuronal: p < 10−8;
N-vs.-Basal squamous: p < 10−12;
N-vs.-Luminal: p < 10−10;
N-vs.-Luminal_Infiltrated: p < 10−9;
N-vs.-Luminal_Papillary: p < 10−12
KIRC N-vs.-ccA subtype: p = 10
−8
N-vs.-ccB subtype: p < 10−8
N-vs.-G 1: p < 10−3
N-vs.-G 2: p < 10−11
N-vs.-G 3: p < 10−9
N-vs.-G 4: p < 10−6
KIRP
N-VS.-Type1 PRCC: p < 10−12
N-VS.-Type2 PRCC: p < 10−7
N-VS.-KIRP CIMP: p < 10−3
N-VS.-Unclassified PRCC: p < 10−3
PRAD
N-vs.-ERG fusion: p < 10−5
N-vs.-ETV1 fusion: p < 10−3
N-vs.-SPOP mutation: p < 10−5
N-vs.-Gleason score 7: p < 10−3
N-vs.-Gleason score 8: p < 10−5
N-vs.-Gleason score 9: p < 10−4
BRCA
N-vs.-IDC: p < 10−12
N-vs.-ILC: p < 10−12
N-vs.-Mixed: p < 10−6
N-vs.-Other: p < 10−7
N-vs.-Mucinous: p < 10−3
N-vs.-Metaplastic: p < 10−3
N-vs.-Medullary: p < 10−3
N-vs.-Luminal: p < 10−12
N-vs.-HER2 Positive: p < 10−10
N-vs.-TNBC: p < 10−12
N-vs.-TNBC-BL1: p < 10−7
N-vs.-TNBC-BL2: p < 10−8
N-vs.-TNBC-IM: p < 10−8
N-vs.-TNBC-LAR: p < 10−3
N-vs.-TNBC-MSL: p < 10−4
N-vs.-TNBC-M: p < 10−10
N-vs.-TNBC-UNS: p < 10−5
N-vs.-Pre-Menopause: p < 10−12
N-vs.-Peri-Menopause: p < 10−6
N-vs.-Post-Menopause: p <
10−12
COAD N-vs.-Adenocarcinoma: p < 10
−12
N-vs.-Mucinous-adenocarcinoma: p < 10−11
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Table 1. Cont.
Tumor Histological Subtypes Molecular Subtypes Tumor Grade Other Patient Conditions
ESCA N-vs.-Adenocarcinoma: p < 10
−12
N-vs.-Squamous-cell-carcinoma: p < 10−12 G 2-vs.-G 3: p < 10
−8
HNSC
N-vs.-G 1: p < 10−12
N-vs.-G 2: p < 10−12
N-vs.-G 3: p < 10−12
N-vs.-G 4: p < 10−5
N-vs.-HPV+ve: p < 10−11
N-vs.-HPV-ve: p < 10−12
LIHC
N-vs.-G 1: p < 10−5
N-vs.-G 2: p < 10−12
N-vs.-G 3: p < 10−12
N-vs.-G 4: p < 10−3
PAAD G1-vs.-G 2: p = 0.014G1-vs.-G3: p = 0.0062
N-vs.-Weekly Drinker: p = 0.025
N-vs.-Occasional Drinker: p < 10−3
N-vs.-Diabetic: p < 10−4
N-vs.-NonDiabetic: p < 10−7
N-vs.-Pancreatitis: p < 10−4
N-vs.-NoPancreatitis: p < 10−7
READ N-vs.-Adenocarcinoma: p < 10
−12
N-vs.-Mucinous-adenocarcinoma: p < 10−3
STAD
N-vs.-Adenocarcinoma (NOS): p < 10−12
N-vs.-Adenocarcinoma (Diffuse): p < 10−10
N-vs.-Adenocarcinoma (Signet Ring): p < 10−3
N-vs.-Intestinal Adenocarcinoma (NOS): p < 10−12
N-vs.-IntestinalAdenocarcinoma (Tubular): p < 10−12
N-vs.-IntestinalAdenocarcinoma (Mucinous): p < 10−4
N-vs.-IntestinalAdenocarcinoma (Papillary): p = 0.017
N-vs.-G 1: p = 0.0057
N-vs.-G 2: p < 10−12
N-vs.-G 3: p < 10−12
G 1-vs.-G 3: p = 0
N-vs.-Tumors (with H. pylori infection): p
< 10−4
N-vs.-Tumors (without H. pylori
infection): p < 10−12
N-vs.-Tumors (Not available): p < 10−12
Int. J. Mol. Sci. 2019, 20, 2228 6 of 19
Table 1. Cont.
Tumor Histological Subtypes Molecular Subtypes Tumor Grade Other Patient Conditions
LUAD
N-vs.-NOS: p < 10−12
N-vs.-Mixed: p < 10−14
N-vs.-LBC-NonMucinous: p < 10−4
N-vs.-SolidPatternPredominant: p = 0.019
N-vs.-Acinar: p < 10−5
N-vs.-LBC-Mucinous: p < 10−5
N-vs.-Mucinous carcinoma: p < 10−3
N-vs.-Papillary: p < 10−4
LUSC
N-vs.-NOS: p < 10−12
N-vs.-Basaloid: p < 10−5
N-vs.-Papillary: p = 0.018
UCEC
N-vs.-Endometrioid: p < 10−12
N-vs.-Serous: p < 10−12
N-vs.-Mixed serous and endometrioid: p < 10−7
N-vs.-Pre-Menopause: p < 10−9
N-vs.-Peri-Menopause: p < 10−4
N-vs.-Post-Menopause: p < 10−12
THCA Classical-VS.-Follicular: p < 10
−5
Tall-VS.-Follicular: p < 10−3
N: normal; p: p-value; amp: amplification; G: grade. All details are given in Supplementary Figure S2.
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In relation to digestive system tumors, COAD tumors showed increased UBE2C levels in
adenocarcinoma and mucinous-adenocarcinoma (Table 1 and Figure S2 panel 3A). In ESCA, UBE2C
expression was increased in both subtypes, including adenocarcinoma and squamous-cell-carcinoma
(Table 1 and Figure S2 panel 3B). The expression in HNSC in all grades is higher than in normal
tissue, particularly for grade 3 tumors (Table 1 and Figure S2 panel 3C). Also, the expression based
on human papilloma virus (HPV) status showed a more statistically significant increase in HPV
negatives than positives compared to normal in this cancer (Table 1 and Figure S2 panel 3D). All
grades of LIHC tumors showed high UBE2C, with grade 2 and 3 more statically significant (Table 1
and Figure S2 panel 3E). In PAAD tumors based on patients’ drinking habits, the expression was
more statistically significant only for occasional drinkers and weekly drinkers (Table 1 and Figure
S2 panel 3F). On the basis of diabetes status, the expression in non-diabetics was more significant
than diabetics when compared to normal (Table 1 and Figure S2 panel 3G), but their comparison with
each other was not statistically significant. On the basis of pancreatitis status, the expression was
more significant in non-pancreatitis than pancreatitis compared to their matched normal (Table 1 and
Figure S2 panel 3H), but the expression was not significant when these two were compared to each
other. In READ, both adenocarcinoma and mucinous-adenocarcinoma showed a significant increase
of expression, with the first one more statistically significant (Table 1 and Figure S2 panel 3I). STAD
tumors showed high UBE2C expression in all conditions with high significance in tumors without H.
pylori infection (Table 1 and Figure S2 panel 3J), but the comparison with each other was not statistically
significant. For its histological subtypes, all of them showed increased levels, with more statistically
significant for intestinal adenocarcinoma-not otherwise specified (NOS), intestinal adenocarcinoma
tubular, and adenocarcinoma NOS with the same change, followed by adenocarcinoma diffuse and
intestinal adenocarcinoma mucinous (Table 1 and Figure S2 panel 3K). Also, all grades of STAD show
significant UBE2C overexpression compared to normal (Table 1).
Regarding lung cancers, while approximately all histological subtypes of LUAD tumors
showed increased UBE2C expression, the increased level was more statistically significant for lung
adenocarcinoma mixed type, followed by lung adenocarcinoma NOS (Table 1 and Figure S2 panel
4A). Regarding LUSC, for its histological subtypes, the increase was more significant for LUSC NOS,
followed by lung basaloid squamous cell carcinoma (Table 1 and Figure S2 panel 4B).
All histological subtypes of UCEC tumors showed a notable UBE2C increase, which was more
statistically significant for serous and endometrioid and then mixed serous and endometrioid (Table 1
and Figure S2 panel 5A). For this cancer type, the UBE2C expression was more significant for
post-menopause (Table 1 and Figure S2 panel 5B).
When we inspected the contribution of smoking habits of cancer patients to UBE2C expression,
we found no difference between smokers and non-smokers in BLCA patients. Nevertheless, the UBE2C
expression level was higher in reformed smokers (>15 years) compared to non-smokers (Figure S2 panel
6A). Regarding smoking habits in ESCA, the expression levels in all conditions were higher than normal,
but was more significant in smokers than non-smokers (Figure S2 panel 6B). In LUAD, the expression
in smokers (reformed smoker2, smokers, and reformed smoker1) showed more significant values than
non-smokers (Figure S2 panel 6C). Regarding LUSC patients based on smoking habits, the expression
in all categories showed an increase compared to normal, which was more significant for reformed
smoker1, smoker, and reformed smoker2. However, there was no statistically significant difference
between smokers and non-smokers in LUSC cancer (Figure S2 panel 6D).
We next investigated UBE2C expression on the basis of patients’ pathological stage in TCGA cancer
types. We found that in COAD, ESCA, HNSC, KICH, READ, STAD, and BLCA, UBE2C expression levels
were significantly higher in early-stages (Figure 2, p-value < 0.05). This indicates a possible involvement
of UBE2C in the initiation of cancer. Furthermore, the expression in BRCA, KIRC, KIRP, LIHC, LUAD,
LUSC, and UCEC was higher in late-stage cancers compared to early stages, representing a possible role
of UBE2C in cancer progression and invasion (Figure 2, cancer without and/or small numbers of normal
matches (when there is only one sample in each stage) were excluded from this analysis).
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2.2. Role of UBE2C Overexpression in Cancer Prognosis
The OS time between UBE2C higher-expression-level and UBE2C lower-expression-level tumors
were compared in TCGA tumor types and data revealed a shorter OS with worse prognosis in patients
with UBE2C higher expression levels compared to its lower expression levels in the following cancers:
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ACC, BRCA, KIRC, KIRP, LGG, LUAD, PAAD, and SKCM (Figure 3, only cancers with significant
changes, p-value < 0.05, a shorter OS with worse prognosis, are given).
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Regarding DFS time in the TCGA tumor types, data showed that UBE2C higher-expression levels
led to worse DFS prognosis in comparison to its lower expression in the following tumors: ACC, KIRC,
KIRP, LGG, LIHC, PAAD, PRAD, THCA, and UCEC. (Figure 4, only cancers with significant changes,
p-value < 0.05, worse DFS prognosis, are given). These data demonstrate that UBE2C overexpression
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2.3. Gene Expression Correlation between UBE2C and Other Genes in Cancers
Our study revealed that the expression of UBE2C has a moderate to very strong positive correlation
with other genes in 27 cancers (Supplementary Table S1 file, all information related to coefficient correlation
and p-value are given in this file and different colors are used to distinguish the correlation as follows:
Strong and very strong positive correlation in green; medium positive correlation in black, weak and very
weak positive correlation in red; and negative correlation in violet). As seen in Supplementary Table S1 file
and Table 2, the positive UBE2C expression correlations are strong to very strong (R between 0.6 and 1 and
p-value < 0.05) for the following genes in all 27 cancers: MYB proto-oncogene like 2 (MYBL2), trophinin
associated protein (TROAP), cell division cycle 20 (CDC20), centromere protein A (CENPA), kinesin family
member C1 (KIFC1), cyclin dependent kinase 1 (CDK1), kinesin family member 4A (KIF4A), and kinesin
family member 20A (KIF20A). In addition, the following genes showed a strong to very strong positive
expression in correlations with UBE2C in 26 cancers, but moderate positive correlations (R between 0.4 and
0.59 and p-value < 0.05, Table 2 and Table S1 file) in one cancer, including TPX2, microtubule nucleation
factor (TPX2), polo like kinase 1 (PLK1), aurora kinase B (AURKB), non-SMC condensin I complex subunit
G (NCAPG), cyclin B1 (CCNB1), spindle and kinetochore associated complex subunit 3 (SKA3), and kinesin
family member 18B (KIF18B). Moreover, some genes showed strong to very strong positive expression
correlations with UBE2C in several cancers while moderate correlations were found in a few cancers among
27 studied cancers as indicated in the Table S1 file and Table 2. Among the 27 cancers, most negative
correlations between UBE2C expression and different genes were observed in the TGCT cancer mentioned
in Table S1 file (in violet) and Table 2, with a strong negative correlation for Testis-specific Y-encoded-like
protein 2 (TSPYL2), ATR serine/threonine kinase (ATR), and CYLD lysine 63 deubiquitinase (CYLD).
Regarding genes which have protein products that have transcription factor binding sites on both
the promoter and enhancer regions of UBE2C, we found forkhead box M1 (FOXM1, two sites with
transcription start site (TSS) distance of +0.1 kb and +158.3 kb), E2F transcription factor 1 (E2F1, TSS
distance: +158.3 kb), RAD51 recombinase (RAD51, two sites with TSS distance of +551.6 kb and
+123.8 kb), and BRCA1 DNA repair associated (BRCA1, TSS distance: +158.3 kb). It is worthwhile to
note that only FOXM1, E2F1, and RAD51 showed positive correlations with UBE2C in all 27 cancers.
These three genes showed similar strong to very strong positive correlations with UBE2C in the different
cancers given in Table 2 and Supplementary data Table S1.
In relation to the expression correlation between UBE2C and tumor suppresser genes including BUB1
mitotic checkpoint serine/threonine kinase B (BUB1B), BRCA1, BRCA2 DNA repair associated (BRCA2),
checkpoint kinase 2 (CHK2), ATM serine/threonine kinase (ATM),ATR, tumor protein p53 (TP53),CYLD, and
TSPYL2, the positive correlation between BUB1B and UBE2C was seen in 26 cancers, but not in TGCT cancer
(Table 2 and Supplementary Data Table S1). Regarding BRCA1 and BRCA2, both of these genes showed
similar strong positive correlations with UBE2C in different cancers (Table 2 and Table S1 file), but a negative
correlation was observed for BRCA1 in THCA and for BRCA2 in TGCT (Table 2 and Supplementary Data
Table S1). CHK2 and TP53 genes showed a positive correlation with UBE2C in several cancers (Table 2 and
Table S1 file) while CHK2 showed a strong negative correlation in KICH and TP53 revealed a very weak
negative correlation in this cancer. Three tumor suppresser genes, including CYLD, ATM, and TSPYL2,
showed a negative correlation with UBE2C in several cancers with a similar moderate to strong negative
correlation for them in the following cancers: LUSC, READ, UCEC, OV, and UCS. It is worthy to note that
TSPYL2 showed down-regulation in most of the 27 cancers (Supplementary Data Figure S3) and also very
weak to strong negative correlation with UBE2C in most of these studied cancers (Table S1 file and Table 2).
Among the genes with a positive expression correlation with UBE2C, some genes that can be considered as
target genes in several cancers. For example, mitochondrial fission regulator 2 (MTFR2 also called FAM54A,
only limited studies in GBM [20] and ovarian cancer [21]), meiotic nuclear divisions 1 (MND1, limited
studies in breast [22] and ovarian cancers [23]), family with sequence similarity 72 member D (FAM72D only
one study in GBM [24]), and POC1 centriolar protein A (POC1A, limited reports in bladder [25], brain [26],
and breast cancer [27]). As seen in Table 3 and Supplementary Figure S4 file, they showed an overexpression,
with alterations across different pathological cancer stages and a worse OS prognosis in several cancers.
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Table 2. Expression correlation between UBE2C and various genes.
Genes with Strong to very Strong Positive
UBE2C Expression Correlations in all 27
Cancers
Genes with Strong to very Strong Positive
UBE2C Expression Correlations in 26
Cancers, but Moderate Positive Correlation
in One Cancer
Genes with Strong to very Strong
Positive UBE2C Expression
Correlations in Several Cancers, but
Moderate in Few Cancers
Gene with Negative Correlation with UBE2C Expression in
TGCT Cancer
MYBL2, TROAP, CDC20, CENPA, KIFC1,
CDK1, KIF4A, and KIF20A.
TPX2, PLK1, AURKB, NCAPG, CCNB1, SKA3,
and KIF18B.
CDCA3, HJURP, UBE2T, MAD2L1,
DLGAP5, MELK, RNASEH2A, KIF23,
FAM72D, and FEN1
KIF2C, CDCA5, CDC25C, BUB1, MTFR2, KIF15, CDKN3, CKS2,
BUB1B, ASF1B, NUF2, PLK4, TTK, POC1A, UBE2S, AUNIP,
NEK2, DSN1, BRCA2, CYLD, ATM, ATR, and TSPYL2
Gene with negative correlation with UBE2C expression in different cancers
Positive expression correlation between UBE2C and genes
having TF binding sites on both promoter and enhancer
regions of UBE2C in different cancers
BRCA1 in THCA
BRCA2 in TGCT
CHK2 in KICH, and THYM
CYLD in COAD, KIRP, LUAD, LUSC, PRAD, READ, SKCM, STAD, THCA, UCEC, ACC, LAML, OV, UCS, THYM, GBM, TGCT
ATM in BLCA, BRCA, COAD, KIRC, LUAD, LUSC, PAAD, READ, STAD, THCA, UCEC, ACC, OV, UCS, THYM, GBM, HNSC, TGCT
ATR in LUAD, SKCM, THCA, UCEC, ACC, OV, UCS, TGCT
TP53 in KICH
TSPYL2 in BLCA, BRCA, COAD, ESCA, KICH, LIHC, LUAD, LUSC, PAAD, PRAD, READ, SKCM, STAD, THCA, UCEC, ACC, OV, UCS,
THYM, LGG, GBM, HNSC, TGCT
BRCA (FOXM1: R = 0.69; E2F1: R = 0.7; RAD51: R = 0.67)
ESCA (FOXM1: R = 0.79; E2F1: R = 0.82; RAD51: R = 0.83)
KICH (FOXM1: R = 0.84; E2F1: R = 0.83; RAD51: R = 0.63)
KIRC (FOXM1: R = 0.73; E2F1: R = 0.7; RAD51: R = 0.72)
LUSC (FOXM1: R = 0.72; E2F1: R = 0.67; RAD51: R = 0.7)
PAAD (FOXM1: R = 0.82; E2F1: R = 0.88; RAD51: R = 0.86)
READ (FOXM1: R = 0.73; E2F1: R = 0.86; RAD51: R = 0.74)
SKCM (FOXM1: R = 0.76; E2F1: R = 0.7, RAD51: R = 67)
UCEC (FOXM1: R = 0.7; E2F1: R = 0.75; RAD51: R = 0.66)
ACC (FOXM1: R = 0.84; E2F1: R = 0.69; RAD51: R = 0.86)
DLBC (FOXM1: R = 0.89; E2F1: R = 0.82; RAD51: R = 0.9)
THYM (FOXM1: R = 0.72; E2F1: R = 0.84; RAD51: R = 0.82)
LGG (FOXM1: R = 0.9; E2F1: R = 0.8; RAD51: R = 0.94)
GBM (FOXM1: R = 0.87; E2F1: R = 0.75; RAD51: R = 0.87)
Positive correlation between UBE2C and tumor suppressor genes in cancers
BUB1B: Strong and very strong (BLCA, BRCA, COAD, ESCA, KICH, KIRC, KIRP, LIHC, LUAD, LUSC, PAAD, READ, SKCM, STAD, UCEC, ACC, DLBC, LAML, UCS, THYM, GBM, HNSC); Moderate
(PRAD, THCA, OV); Weak (LGG)
BRCA1: Strong and very strong (COAD, ESCA, LUAD, LUSC, PAAD, READ, ACC, DLBC, LAML, LGG, GBM); Moderate (BLCA, KICH, KIRC, KIRP, LIHC, PRAD, SKCM, STAD, OV, UCS, THYM, HNSC);
Weak (BRCA and UCEC); Very weak (TGCT)
BRCA2: Strong and very strong (COAD, ESCA, READ, DLBC, LAML, LGG, GBM); Moderate (BLCA, BRCA, KIRP, LIHC, LUAD, LUSC, PAAD, SKCM, STAD, UCEC, ACC, OV, and UCS); Weak (KICH,
KIRC, PRAD, THCA, HNSC); Very weak (THYM)
CHK2: Strong and very strong (COAD, LUSC, PAAD, READ, UCEC, DLBC, LAML, LGG, GBM, TGCT); Moderate (BLCA, BRCA, ESCA, KIRC, LUAD, SKCM, STAD, UCS, HNSC); Weak (LIHC, PRAD,
THCA, ACC); Very weak (KIRP and OV)
TP53: Strong and very strong (ESCA, PAAD, READ, DLBC, LAML, THYM, LGG, GBM, TGCT); Moderate (COAD, LIHC, LUSC, UCS); Weak (KIRP, LUAD, STAD, THCA, UCEC, ACC); Very weak (BLCA,
BRCA, KIRC, PRAD, SKCM, OV, HNSC)
ATM: Weak (DLBC); Very weak (ESCA, KICH, KIRP, LIHC, PRAD, SKCM, DLBC, LGG)
ATR: Strong and very strong (DLBC and LAML); Moderate (ESCA, PAAD, THYM); Weak (BLCA, COAD, KICH, KIRC, STAD, HNSC); Very weak (BRCA, KIRP, LIHC, LUSC, PRAD, READ, LGG, GBM)
CYLD: Weak (PAAD, DLBC); Very weak (BLCA, BRCA, ESCA, KICH, LIHC, LGG, HNSC)
More details are given in Supplementary Table S1.
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Table 3. Statistically significant overexpression of different proposed target genes in most common cancers.
Genes Cancers with Overexpression of Proposed Cancer Target Genes(Normal-vs.-Primary)
OS (Higher Expression
Levels-vs.-Lower Expression Levels)
MTFR2 (FAM54A)
BLCA (p-value < 10−16), BRCA (p-value < 10−12), Metastatic breast cancer (MYC-amplification
(+) vs. MYC-amplification (-): p-value < 10−12, CCND1-amplification (+) vs. CCND1-amplification
(−): p-value < 10−12, ERBB2-amplification (+) vs. ERBB2-amplification (−): p-value < 10−12), CESC
(p-value < 10−12), COAD (p-value < 10−12), ESCA (p-value < 10−12), GBM (p-value < 10−12),
HNSC (p-value < 10−12), KICH (p-value = 0.017), KIRC (p-value < 10−12), KIRP (p-value < 10−12),
LIHC (p-value < 10−12), LUAD (p-value < 10−12), LUSC (p-value < 10−12), PRAD (p-value < 10−5,
Molecular subtypes of PRAD: Normal-vs.-ERG fusion: p-value < 10−3, Normal-vs.-ETV1 fusion:
p-value < 10−3, Normal-vs.-SPOP mutation: p-value < 10−3), Metastatic prostate cancer
(ERG-fusion (+) vs. ERG-fusion (-): p-value < 10−12, AR-amplification (+) vs. AR-amplification (−):
p-value < 10−12), READ (p-value < 10−6), STAD (p-value < 10−12), UCEC (p-value < 10−12).
ACC (p-value < 0.0001)
LGG (p-value < 0.0001)
KICH (p-value < 0.0001)
KIRC (p-value < 0.0001)
KIRP (p-value < 0.0001)
LIHC (p-value = 0.00018)
UCEC (p-value = 0.043)
MND1
BLCA (p-value < 10−6), BRCA (p-value < 10−12), COAD (p-value < 10−12), ESCA (p-value <
10−12), CESC (p-value = p-value < 10−12), HNSC (p-value < 10−12), KICH (p-value < 10−9), KIRC
(p-value < 10−12), KIRP (Normal-vs.-Primary: p-value < 10−15), LIHC (p-value < 10−12), LUAD
(p-value < 10−12), LUSC (p-value < 10−12), PRAD (p-value < 10−8, Molecular subtypes of PRAD:
Normal-vs.-ERG fusion: p-value < 10−4, Normal-vs.-ETV1 fusion: p-value < 10−3,
Normal-vs.-ETV4 fusion: p-value < 10−4), READ (p-value < 10−8), STAD (p-value < 10−12), THCA
(p-value = 0.0348), UCEC (p-value < 10−12).
ACC (p-value = 0.016)
LGG (p-value < 0.0001)
KICH (p-value = 0.00025)
KIRC (p-value = 0.046)
KIRP (p-value < 0.0001)
LIHC (p-value = 0.0054)
LUAD (p-value = 0.0034)
PAAD (p-value = 0.048)
SKCM (p-value = 0.047)
FAM72D
BLCA (p-value < 10−12), BRCA (p-value < 10−12), Metastatic breast cancer (amplification (+) vs.
ERBB2-amplification (−): p-value < 10−2), COAD (p-value < 10−12), ESCA (p-value < 10−12), GBM
(p-value < 10−12), HNSC (p-value < 10−12), KIRC (p-value < 10−12), KIRP (p-value < 10−13), LIHC
(p-value < 10−12), LUAD (p-value < 10−12), LUSC (p-value < 10−12), PRAD (p-value < 10−10,
Molecular subtypes of PRAD: Normal-vs.-ERG fusion: p-value < 10−7, Normal-vs.-ETV1 fusion:
p-value < 10−3, Normal-vs.-SPOP mutation: p-value < 10−5), READ (p-value < 10−11), STAD
(p-value < 10−12), UCEC (p-value < 10−12).
ACC (p-value < 0.0001)
LGG (p-value < 0.0001)
BRCA (p-value = 0.041)
KICH (p-value = 0.0012)
KIRC (p-value < 0.0001)
KIRP (p-value < 0.0001)
LIHC (p-value = 0.0024)
LUAD (p-value = 0.009)
POC1A
BLCA (p-value < 10−10), BRCA (p-value < 10−12), Metastatic breast cancer (amplification (+) vs.
ERBB2-amplification (−): p-value: 0.0279), CESC (p-value < 10−9), COAD (p-value < 10−12), ESCA
(p-value < 10−11), GBM (p-value < 10−12), HNSC (p-value < 10−12), KICH (p-value: 0.016), KIRP
(p-value < 10−5), LIHC (p-value < 10−12), LUAD (p-value < 10−12), LUSC (p-value < 10−12), PRAD
(p-value < 10−15, Molecular subtypes of PRAD: Normal-vs.-ERG fusion: p-value < 10−7,
Normal-vs.-ETV1 fusion: p-value < 10−3, Normal-vs.-ETV4 fusion: p-value < 10−2,
Normal-vs.-SPOP mutation: p-value < 10−10), READ (p-value < 10−5), STAD (p-value < 10−16),
THCA (p-value < 10−8), UCEC (p-value < 10−12).
ACC (p-value < 0.0001)
LGG (p-value < 0.0001)
KICH (p-value = 0.00017)
KIRC (p-value < 0.0001)
KIRP (p-value < 0.0001)
LIHC (p-value = 0.028)
LUAD (p-value = 0.0094)
OV (p-value = 0.039)
PAAD (p-value = 0.012)
SKCM (p-value = 0.0039)
STAD (p-value = 0.013)
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2.4. UBE2C Protein Network
Genes with strong or very strong positive correlations with UBE2C expression in the 27 cancers
(see Methods Section, Table 2, and Supplementary Table S1) and also some negative correlations with
important tumor suppressor genes were identified in the UBE2C protein network. Data from STRING
database revealed that all these proteins (products of all genes listed in Table S1 file) are in the same protein
network (Figure 5, only proteins with strong and very strong positive correlations with UBE2C in most of the
27 cancers, some tumor suppressor proteins, and protein with TF bindings site onUBE2C are shown). Proteins
in this network are involved in different pathways, including cell cycle, oocyte meiosis, p53 signaling pathway,
double-strand break repair, oocyte development and differentiation, FoxO signaling pathway, ubiquitin
mediated proteolysis, cellular senescence, and progesterone-mediated oocyte maturation among others
(Table 4 and Supplementary data Table S2). All pathways that UBE2C is mainly involved with are indicated
in red (Supplementary Table S2). Proteins with TF binding sites on both the promoter and enhancer regions of
UBE2C (FOXM1, E2F1, RAD51, and BRCA1) are also involved in the UBE2C network. As described in Table 4
and in Supplementary data Table S2, these proteins were found to also be involved in most pathways related
to the UBE2C protein network. Among the UBE2C protein partners, TSPYL2 (a member of the testis-specific
protein Y-encoded) is a tumor suppressor protein which acts in the chromatin remodeling process. This
protein is also involved in most pathways with the involvement of UBE2C (Supplementary data Table S2).
As TSPYL2 was under-expressed in most cancers (Supplementary data Figure S3) and showed negative
correlations with UBE2C that were very weak to moderate (Table 2 and Supplementary data Table S1),
we analyzed the RNA–RNA association between TSPYL and UBE2C using RNAup webserver and also
RNA–protein interactions using RPISeq. These analyses showed that TSPYL2 is not only involved in the
UBE2C protein network, but also in RNA–RNA interactions and RNA–protein interactions with UBE2C
(Figure S5 panel A and B). Moreover, these two proteins were in the same subcellular localization. We also
found a D-box (one of the recognition amino acid sequences identified by APC/C in the ubiquitin–proteasome
pathway) in amino acids 45 to 48 in TSPYL2 protein using the GPS-ARM tool (Figure S5 panel C).Int. J. M l. Sci. 2018, 19, x 15 of 21 
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Table 4. Biological pathways related to proteins involved in UBE2C network.
KEGG Number Cellular Process Protein Gene
hsa04110 Cell cycle
ATM, ATR, BUB1, BUB1B, CCNA2, CCNB1,
CCNB2, CDC20, CDC25A, CDC25C, CDK1,
CHEK1, E2F1, MAD2L1, ORC6, PLK1, TP53,
TTK, CHEK2
hsa04114 Oocyte meiosis AURKA, BUB1, CCNB1, CCNB2, CDC20,CDC25C, CDK1, MAD2L1, PLK1, SGOL1
hsa04914 Progesterone-mediated oocytematuration
AURKA, BUB1, CCNA2, CCNB1, CCNB2,
CDC25A, CDC25C, CDK1, MAD2L1, PLK1
hsa04218 Cellular senescence
ATM, ATR, CCNA2, CCNB1, CCNB2, CCNE1,
CCNE2, CDC25A, CDK1, CHEK1, CHEK2,
E2F1, FOXM1, MYBL2, TP53
hsa04115 p53 signaling pathway ATM, ATR, CCNB1, CCNB2, CDK1, CDKN1A,CHEK1, CHEK2, GTSE1, MDM2, TP53
hsa04120 Ubiquitin mediated proteolysis BRCA1, CDC20, UBE2C, UBE2S
hsa04068 FoxO signaling pathway ATM, CCNB1, CCNB2, CDKN1B, PLK1, PLK4
hsa03030 DNA replication FEN1, RNASEH2A
hsa03440 Homologous recombination ATM, BRCA1, BRCA2, RAD54L
hsa01522 Endocrine resistance E2F1, TP53
hsa03460 Fanconi anemia pathway ATR, BRCA1, BRCA2, UBE2T
hsa05200 Pathways in cancer BRCA2, CKS2, E2F1, TP53
hsa04151 PI3K-Akt signaling pathway BRCA1, TP53
hsa05202 Transcriptional misregulation in cancer ATM, TP53
hsa03410 Base excision repair FEN1
hsa05222 Small cell lung cancer CKS2, E2F1, TP53
hsa05215 Prostate cancer E2F1, TP53
hsa05226 Gastric cancer E2F1, TP53
hsa05220 Chronic myeloid leukemia E2F1, TP53
hsa05219 Bladder cancer E2F1, TP53
hsa05214 Glioma E2F1, TP53
hsa05218 Melanoma E2F1, TP53
hsa05212 Pancreatic cancer BRCA2, E2F1, TP53
hsa05224 Breast cancer BRCA1, BRCA2, E2F1, TP53
hsa05223 Non-small cell lung cancer E2F1, TP53
3. Discussion
UBE2C is a member of the E2 ubiquitin-conjugating enzyme family, it plays a key role in the
ubiquitination system in cooperation with APC/C. It is involved in mitotic cyclin B degradation,
promoting the transition from the M phase to the G1 phase of the cell cycle [28,29]. Therefore, it is
likely that aberrant UBE2C overexpression, leading to changes in ubiquitination, might be involved in
uncontrolled cell proliferation, which is one of the main features of cancers.
The current study shows, for the first time, a global analysis of UBE2C expression in a wide
array of tumors. Our results demonstrated that UBE2C is upregulated in all 27 different cancers
examined and this is in agreement with previous reports showing the increased somatic expression
of UBE2C in various tumor types. Indeed, the overexpression of UBE2C was previously reported in
hepatocellular carcinoma, thyroid, colon, breast, and lung cancer [8–13] and our data confirmed this
upregulation (Figure 1). To give an example, in a study conducted by Qin et al., the overexpression
of UBE2C was found in breast cancer, including the basal-like (BL) subtype [30], and our study also
showed this significant upregulation in both BL1 and BL2. Importantly, our investigation showed
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that overexpression of UBE2C is a common feature of all 27 human cancers tested in this study,
suggesting it acts as a proto-oncogene. Moreover, the current study revealed the significant UBE2C
overexpression across the histological and molecular subtypes of different tumors mentioned in the
results and also possible associations between this expression and different patient conditions, such as
drinking and smoking habits in PAAD and LUAD, respectively. UBE2C expression, based on patients’
pathological stages, showed that UBE2C overexpression can be involved in tumor progression and
invasion. Our data broaden the observations of previous reports [15,30,31].
We showed that patients with higher expression of UBE2C had a shorter overall survival time and
worse prognosis, and UBE2C higher-expression levels also resulted in worse DFS prognosis in many
cancers, confirming that UBE2C overexpression results in poor clinical outcomes in many tumors.
As an example, Qin et al. found that the UBE2C upregulation was associated with poor prognosis in
breast cancer [30], and our data also revealed this issue as shown in Figure 3.
Furthermore, our study identified coexpression genes associated with the UBE2C protein
network. Those genes with strong and very strong positive correlations with UBE2C expression in
all cancers (Table 2) are involved in the cell cycle process. These include members of the kinesin
family (KIF20A, KIF18B, KIFC1, and KIF4A), with roles in mitotic spindle maintenance, chromosome
segregation, and microtubule depolarization [32,33]; AURKB as a regulator of chromosome segregation
during mitosis [34]; TROAP (a member of the cell adhesion molecule complex) with a role in centrosome
integrity during cell cycle progression [35]; TPX2 (a microtubule-associated protein) having a key
function in mitotic spindle formation [36]; PLK1 as a regulator of cell division and maintenance of
genome stability and spindle assembly, and DNA damage response) [37,38]; CDK1 (a cyclin-dependent
kinase), involved in cell division with important functions in mitosis and driving cells into the S
phase [39]; CENPA (a key component of the inner kinetochore plate), playing a role in chromosome
segregation during oocyte meiosis) [40]; CDC20 as an activator of APC/C during mitosis for mitosis
progression [41]; MYBL2, involved in cell cycle progression, cell survival, and cell differentiation [42];
BUB1B as a vital component of the mitotic checkpoint complex [43]; CCNB1, having an essential role in
the transition of the cell cycle from G2 phase to mitosis [44,45]; NCAPG (a mitosis-related chromosome
condensation protein) involved in the condensin I complex [46]; SKA3, controlling the correct exit from
meiosis, migration of meiotic spindle, and stability of anaphase spindle [47]. Our data highlight the
UBE2C network as one of the major protein networks involved in cancer and further investigation on
their function in tumors might shed light onto new therapeutic strategies for cancer.
Interestingly, we also highlighted as UBE2C coxpressed genes the transcription factors, FOXM1,
E2F1, and RAD51, which have their binding sites on the UBE2C promoter and enhancer regions,
suggesting they are transcriptional regulators of this gene. Our results are in agreement with a
previous report of a positive association of FOXM1 with UBE2C in normal tissues and in tumors [48].
The identification of RAD51, which has a key role in the homologous recombination and repair of
DNA [49], and mainly E2F1 could be particularly relevant since E2F1 contributes to the activation of
genes involved in G1/S progression [50–53].
We also found a significant correlation between UBE2C and other important regulators of the
cell cycle, including CDC20, which was previously identified as being co-expressed with UBE2C [54].
These data suggest that other genes identified in this study as part of the UBE2C protein network might
play a role in many tumors. In particular, our data highlighted MTFR2, MND1, FAM72D, and POC1A
as genes whose expression correlates with worse OS prognosis, suggesting their possible involvement
in tumor progression and invasion.
In conclusion, the current study showed that UBE2C can be considered as a general tumor
marker and study of its related pathways can help to discover common therapeutic targets for cancers.
However, further functional studies are required to clarify the role of UBE2C in cancers.
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4. Materials and Methods
In the current study, our investigations were performed using different bioinformatics tools and
databases, including GEPIA [55] (a webserver which extracts data from the Cancer Genome Atlas
(TCGA) data portal and the GTEx database of normal tissues. http://gepia.cancer-pku.cn), UALCAN
(an interactive web portal for the in-depth analysis of TCGA gene expression data, http://ualcan.path.uab.
edu) [56], and STRING databases (functional protein association networks (https://string-db.org/) [57]).
Here, we report the following investigations: UBE2C expression levels across all cancers and their
subtypes, its differential gene expression analysis at different pathological stages, correlation between
its expression and cancer prognosis in cancers, overall survival (OS) and the disease-free survival (DFS)
analysis on the basis of UBE2C gene expression, investigation of genes with similar UBE2C expression
patterns, and their associations in the UBE2C protein network.
To investigate UBE2C expression across 27 human tumor types compared to normal matches,
we used the GEPIA webserver. One advantage of GEPIA is that it also uses normal data from the
GTEx project to provides a reliable baseline for comparison. In most cancer research, normal tissues
are prepared from areas adjacent to tumors, but they may be pre-cancerous tissue and not truly
normal, healthy tissue. UBE2C expression between tumors, their matched normal, and data from
the GTEX database in 27 tumor types were compared. These tumors included ACC, BLCA, BRCA,
COAD, DLBC, ESCA, GBM, HNSC, KICH, KIRC, KIRP, LAML, LGG, LIHC, LUAD, LUSC, OV, PAAD,
PRAD, READ, SKCM, STAD, TGCT, THCA, THYM, UCEC, and UCS. Six tumor types were excluded
from the study (where differential expression was considered) due to their small numbers (13 and
lower) or lack of normal samples, including cholangio carcinoma (CHOL), cervical squamous cell
carcinoma and endocervical adenocarcinoma (CESC), mesothelioma (MESO), pheochromocytoma and
paraganglioma (PCPG), sarcoma (SARC), and uveal melanoma (UVM). Regarding parameter options,
we used the ANOVA statistical method for differential gene expression analysis, selected log2(TPM + 1)
transformed expression data for plotting, TCGA tumors compared to TCGA normal and GTEx normal
for matched normal data in plotting, |log2FC| cutoff of 1, and a q-value cutoff of 0.01. Also, for cancers
with different subtypes and conditions, we analyzed them using the UALCAN webserver.
To provide UBE2C expression box plots on the basis of patients’ pathological stage (stage I, stage II,
stage III, and stage IV group) in TCGA cancer types, we used the UALCAN webserver to get data
from TCGA. In this analysis, cancers without normal matches or below two numbers in each stage
were excluded from analysis.
Overall survival (OS) and the disease-free survival (DFS) analysis were also performed on the basis
of UBE2C gene expression. Regarding hypothesis test, the GEPIA considers the Log-rank test. For this,
we selected a hazards ratio (HR) based on the Cox PH model and also the 95% confidence interval
information to show the 95% confidence interval (CI) as the dotted line. TheUBE2C expression threshold
of 50% (median value) was determined to split the UBE2C high-expression and low-expression cohorts.
Therefore, samples with UBE2C expression levels higher and lower than 50% were applied as the
high-expression cohort (cutoff-high) and the low-expression cohort (cutoff-low), respectively.
Correlation analysis between UBE2C and other genes was performed by pair-wise gene expression
correlation analysis with the expression data of TCGA and GTEx, using the method of the Pearson
correlation coefficient. At first, we searched for moderate, strong, and very strong UBE2C expression
correlations (the Pearson correlation coefficient between 0.4 and 1) with other genes on average in all
27 caners. Then, we investigated the UBE2C expression correlations with each gene individually in
each cancer to see the exact correlation. We considered the following correlation coefficients: 0.00–0.19
as very weak, 0.20–0.39 as weak, 0.40–0.59 as fairly strong (also called moderate), 0.60–0.79 as strong,
and 0.80–1.0 as very strong.
To provide the UBE2C protein network, the STRING database was used and most genes with
medium to very strong correlations with UBE2C (extracted from TCGA cancer types using GEPIA)
and also some important tumor suppresser proteins, such as ATR, ATM, BUB1B, BRCA1/2, CHK2,
and CYLD, were searched in STRING.
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To predict the RNA–RNA association and RNA–protein interaction between TSPYL and UBE2C,
we used the RNAup webserver (http://rna.tbi.univie.ac.at//cgi-bin/RNAWebSuite/RNAup.cgi) and
RPISeq (http://pridb.gdcb.iastate.edu/RPISeq/), respectively. Also, to search for a D-box (one of the
recognition amino acid sequences to be identified by APC/C in the ubiquitin–proteasome pathway) in
TSPYL2 protein, we used the GPS-ARM tool (http://arm.biocuckoo.org/down.php).
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/20/9/2228/s1.
Author Contributions: H.D.: Conceptualization, data analysis, writing, D.D.: Technical support, M.C.: Data
supervision, editing manuscript; S.O.: Supervision of the project, review, and editing the manuscript.
Funding: AIRC IG 2017 Id.20240 and IIGM institutional funds to SO and AIRC MGAF Id.20566 to MC.
Acknowledgments: We thank all members of the laboratory for useful discussions.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Akutsu, M.; Dikic, I.; Bremm, A. Ubiquitin chain diversity at a glance. J. Cell. Sci. 2016, 129, 875–880.
[CrossRef]
2. Clague, M.J.; Urbe, S. Ubiquitin: Same molecule, different degradation pathways. Cell 2010, 143, 682–685.
[CrossRef]
3. Meyer, H.J.; Rape, M. Enhanced protein degradation by branched ubiquitin chains. Cell 2014, 157, 910–921.
[CrossRef]
4. Clague, M.J.; Barsukov, I.; Coulson, J.M.; Liu, H.; Rigden, D.J.; Urbe, S. Deubiquitylases from genes to
organism. Physiol. Rev. 2013, 93, 1289–1315. [CrossRef]
5. Clague, M.J.; Heride, C.; Urbe, S. The demographics of the ubiquitin system. Trends Cell Biol. 2015, 25, 417–426.
[CrossRef]
6. Rousseau, A.; Bertolotti, A. Regulation of proteasome assembly and activity in health and disease. Nat. Rev.
Mol. Cell Biol. 2018, 19, 697–712. [CrossRef]
7. Schmidt, M.; Finley, D. Regulation of proteasome activity in health and disease. Biochim. Biophys. Acta
2014, 1843, 13–25. [CrossRef]
8. Ieta, K.; Ojima, E.; Tanaka, F.; Nakamura, Y.; Haraguchi, N.; Mimori, K.; Inoue, H.; Kuwano, H.;
Mori, M. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to
ubiquitin-conjugating enzyme E2C gene expression. Int. J. Cancer 2007, 121, 33–38. [CrossRef]
9. Pallante, P.; Berlingieri, M.T.; Troncone, G.; Kruhoffer, M.; Orntoft, T.F.; Viglietto, G.; Caleo, A.; Migliaccio, I.;
Decaussin-Petrucci, M.; Santoro, M.; et al. UbcH10 overexpression may represent a marker of anaplastic
thyroid carcinomas. Br. J. Cancer 2005, 93, 464–471. [CrossRef]
10. Fujita, T.; Ikeda, H.; Taira, N.; Hatoh, S.; Naito, M.; Doihara, H. Overexpression of UbcH10 alternates the cell
cycle profile and accelerate the tumor proliferation in colon cancer. BMC Cancer 2009, 9, 87. [CrossRef]
11. Berlingieri, M.T.; Pallante, P.; Sboner, A.; Barbareschi, M.; Bianco, M.; Ferraro, A.; Mansueto, G.; Borbone, E.;
Guerriero, E.; Troncone, G.; et al. UbcH10 is overexpressed in malignant breast carcinomas. Eur. J. Cancer
2007, 43, 2729–2735. [CrossRef]
12. Perrotta, I.; Bruno, L.; Maltese, L.; Russo, E.; Donato, A.; Donato, G. Immunohistochemical analysis of the
ubiquitin-conjugating enzyme UbcH10 in lung cancer: A useful tool for diagnosis and therapy. J. Histochem.
Cytochem. 2012, 60, 359–365. [CrossRef]
13. Jiang, L.; Huang, C.G.; Lu, Y.C.; Luo, C.; Hu, G.H.; Liu, H.M.; Chen, J.X.; Han, H.X. Expression of
ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors. Brain Res. 2008, 1201, 161–166. [CrossRef]
14. Bose, M.V.; Gopisetty, G.; Selvaluxmy, G.; Rajkumar, T. Dominant negative Ubiquitin-conjugating enzyme
E2C sensitizes cervical cancer cells to radiation. Int. J. Radiat. Biol. 2012, 88, 629–634. [CrossRef]
15. Xie, C.; Powell, C.; Yao, M.; Wu, J.; Dong, Q. Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker.
Int. J. Biochem. Cell Biol. 2014, 47, 113–117. [CrossRef]
16. van Ree, J.H.; Jeganathan, K.B.; Malureanu, L.; van Deursen, J.M. Overexpression of the E2
ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J. Cell Biol.
2010, 188, 83–100. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 2228 18 of 19
17. Chen, S.; Chen, Y.; Hu, C.; Jing, H.; Cao, Y.; Liu, X. Association of clinicopathological features with UbcH10
expression in colorectal cancer. J. Cancer Res. Clin. Oncol. 2010, 136, 419–426. [CrossRef]
18. Psyrri, A.; Kalogeras, K.T.; Kronenwett, R.; Wirtz, R.M.; Batistatou, A.; Bournakis, E.; Timotheadou, E.;
Gogas, H.; Aravantinos, G.; Christodoulou, C.; et al. Prognostic significance of UBE2C mRNA expression
in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Ann. Oncol.
2012, 23, 1422–1427. [CrossRef]
19. Zhao, Z.K.; Wu, W.G.; Chen, L.; Dong, P.; Gu, J.; Mu, J.S.; Yang, J.H.; Liu, Y.B. Expression of UbcH10 in
pancreatic ductal adenocarcinoma and its correlation with prognosis. Tumor. Biol. 2013, 34, 1473–1477.
[CrossRef]
20. Wang, J.; Xie, Y.; Bai, X.; Wang, N.; Yu, H.; Deng, Z.; Lian, M.; Yu, S.; Liu, H.; Xie, W.; et al. Targeting dual
specificity protein kinase TTK attenuates tumorigenesis of glioblastoma. Oncotarget 2018, 9, 3081–3088.
[CrossRef]
21. Villegas-Ruiz, V.; Juarez-Mendez, S. Data Mining for Identification of Molecular Targets in Ovarian Cancer.
Asian Pac. J. Cancer Prev. 2016, 17, 1691–1699. [CrossRef]
22. Neapolitan, R.E.; Jiang, X. Study of integrated heterogeneous data reveals prognostic power of gene
expression for breast cancer survival. Plos ONE 2015, 10, e0117658. [CrossRef]
23. Yeganeh, P.N.; Richardson, C.; Bahrani-Mostafavi, Z.; Tait, D.L.; Mostafavi, M.T. Dysregulation of AKT3
along with a small panel of mRNAs stratifies high-grade serous ovarian cancer from both normal epithelia
and benign tumor tissues. Genes Cancer 2017, 8, 784–798.
24. Rahane, C.S.; Kutzner, A.; Heese, K. A cancer tissue-specific FAM72 expression profile defines a novel
glioblastoma multiform (GBM) gene-mutation signature. J. Neurooncol. 2019, 141, 57–70. [CrossRef]
25. Descotes, F.; Dessen, P.; Bringuier, P.P.; Decaussin, M.; Martin, P.M.; Adams, M.; Villers, A.; Lechevallier, E.;
Rebillard, X.; Rodriguez-Lafrasse, C.; et al. Microarray gene expression profiling and analysis of bladder
cancer supports the sub-classification of T1 tumors into T1a and T1b stages. Bju. Int. 2014, 113, 333–342.
[CrossRef]
26. Marie, S.K.; Okamoto, O.K.; Uno, M.; Hasegawa, A.P.; Oba-Shinjo, S.M.; Cohen, T.; Camargo, A.A.; Kosoy, A.;
Carlotti, C.G. Jr.; Toledo, S.; et al. Maternal embryonic leucine zipper kinase transcript abundance correlates
with malignancy grade in human astrocytomas. Int. J. Cancer 2008, 122, 807–815. [CrossRef]
27. Zhang, P.; Mourad, R.; Xiang, Y.; Huang, K.; Huang, T.; Nephew, K.; Liu, Y.; Li, L. A dynamic time order
network for time-series gene expression data analysis. BMC Syst. Biol. 2012, 6 (Suppl. 3), S9. [CrossRef]
28. Townsley, F.M.; Aristarkhov, A.; Beck, S.; Hershko, A.; Ruderman, J.V. Dominant-negative cyclin-selective
ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc. Natl. Acad. Sci. USA 1997, 94, 2362–2367.
[CrossRef]
29. Lin, Y.; Hwang, W.C.; Basavappa, R. Structural and functional analysis of the human mitotic-specific
ubiquitin-conjugating enzyme, UbcH10. J. Biol. Chem. 2002, 277, 21913–21921. [CrossRef]
30. Qin, T.; Huang, G.; Chi, L.; Sui, S.; Song, C.; Li, N.; Sun, S.; Li, N.; Zhang, M.; Zhao, Z.; et al. Exceptionally
high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1.
Biomed. Pharm. 2017, 95, 649–655. [CrossRef]
31. Mo, C.H.; Gao, L.; Zhu, X.F.; Wei, K.L.; Zeng, J.J.; Chen, G.; Feng, Z.B. The clinicopathological significance of
UBE2C in breast cancer: A study based on immunohistochemistry, microarray and RNA-sequencing data.
Cancer Cell Int. 2017, 17, 83. [CrossRef]
32. Sharp, D.J.; Rogers, G.C.; Scholey, J.M. Microtubule motors in mitosis. Nature 2000, 407, 41–47. [CrossRef]
33. Miki, H.; Setou, M.; Kaneshiro, K.; Hirokawa, N. All kinesin superfamily protein, KIF, genes in mouse and
human. Proc. Natl. Acad. Sci. USA 2001, 98, 7004–7011. [CrossRef]
34. Wiseman, S.M.; Masoudi, H.; Niblock, P.; Turbin, D.; Rajput, A.; Hay, J.; Bugis, S.; Filipenko, D.; Huntsman, D.;
Gilks, B. Anaplastic thyroid carcinoma: Expression profile of targets for therapy offers new insights for
disease treatment. Ann. Surg. Oncol. 2007, 14, 719–729. [CrossRef]
35. Yang, S.; Liu, X.; Yin, Y.; Fukuda, M.N.; Zhou, J. Tastin is required for bipolar spindle assembly and centrosome
integrity during mitosis. Faseb. J. 2008, 22, 1960–1972. [CrossRef]
36. Kufer, T.A.; Sillje, H.H.; Korner, R.; Gruss, O.J.; Meraldi, P.; Nigg, E.A. Human TPX2 is required for targeting
Aurora-A kinase to the spindle. J. Cell. Biol. 2002, 158, 617–623. [CrossRef]
37. Lens, S.M.; Voest, E.E.; Medema, R.H. Shared and separate functions of polo-like kinases and aurora kinases
in cancer. Nat. Rev. Cancer 2010, 10, 825–841. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 2228 19 of 19
38. Mundt, K.E.; Golsteyn, R.M.; Lane, H.A.; Nigg, E.A. On the regulation and function of human polo-like
kinase 1 (PLK1): Effects of overexpression on cell cycle progression. Biochem. Biophys. Res. Commun.
1997, 239, 377–385. [CrossRef]
39. Diril, M.K.; Ratnacaram, C.K.; Padmakumar, V.C.; Du, T.; Wasser, M.; Coppola, V.; Tessarollo, L.; Kaldis, P.
Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but
not for liver regeneration. Proc. Natl. Acad. Sci. USA 2012, 109, 3826–3831. [CrossRef]
40. Li, L.; Qi, S.T.; Sun, Q.Y.; Chen, S.L. CENP-A regulates chromosome segregation during the first meiosis of
mouse oocytes. J. Huazhong Univ. Sci. Technol. Med. Sci. 2017, 37, 313–318. [CrossRef]
41. Wang, Z.; Wan, L.; Zhong, J.; Inuzuka, H.; Liu, P.; Sarkar, F.H.; Wei, W. Cdc20: A potential novel therapeutic
target for cancer treatment. Curr. Pharm. Des. 2013, 19, 3210–3214. [CrossRef]
42. Musa, J.; Aynaud, M.M.; Mirabeau, O.; Delattre, O.; Grunewald, T.G. MYBL2 (B-Myb): A central regulator of
cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017, 8, e2895.
[CrossRef]
43. Musacchio, A.; Salmon, E.D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol.
2007, 8, 379–393. [CrossRef]
44. Krek, W.; Nigg, E.A. Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M
transitions of the cell cycle: Identification of major phosphorylation sites. Embo J. 1991, 10, 305–316.
[CrossRef]
45. Morgan, D.O. Principles of CDK regulation. Nature 1995, 374, 131–134. [CrossRef]
46. Eberlein, A.; Takasuga, A.; Setoguchi, K.; Pfuhl, R.; Flisikowski, K.; Fries, R.; Klopp, N.; Furbass, R.;
Weikard, R.; Kuhn, C. Dissection of genetic factors modulating fetal growth in cattle indicates a substantial
role of the non-SMC condensin I complex, subunit G (NCAPG) gene. Genetics 2009, 183, 951–964. [CrossRef]
47. Hu, R.; Wang, M.Q.; Niu, W.B.; Wang, Y.J.; Liu, Y.Y.; Liu, L.Y.; Wang, M.; Zhong, J.; You, H.Y.; Wu, X.H.;
et al. SKA3 promotes cell proliferation and migration in cervical cancer by activating the PI3K/Akt signaling
pathway. Cancer Cell Int. 2018, 18, 183. [CrossRef]
48. Nicolau-Neto, P.; Palumbo, A.; De Martino, M.; Esposito, F.; de Almeida Simao, T.; Fusco, A.; Nasciutti, L.E.;
Meireles Da Costa, N.; Ribeiro Pinto, L.F. UBE2C Is a Transcriptional Target of the Cell Cycle Regulator
FOXM1. Genes (Basel) 2018, 9, 188. [CrossRef]
49. Petermann, E.; Orta, M.L.; Issaeva, N.; Schultz, N.; Helleday, T. Hydroxyurea-stalled replication forks
become progressively inactivated and require two different RAD51-mediated pathways for restart and repair.
Mol. Cell 2010, 37, 492–502. [CrossRef]
50. Helin, K. Regulation of cell proliferation by the E2F transcription factors. Curr. Opin. Genet. Dev. 1998, 8, 28–35.
[CrossRef]
51. Dyson, N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998, 12, 2245–2262. [CrossRef]
52. Harbour, J.W.; Dean, D.C. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev.
2000, 14, 2393–2409. [CrossRef]
53. Trimarchi, J.M.; Lees, J.A. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 2002, 3, 11–20. [CrossRef]
54. Nath, S.; Banerjee, T.; Sen, D.; Das, T.; Roychoudhury, S. Spindle assembly checkpoint protein Cdc20 transcriptionally
activates expression of ubiquitin carrier protein UbcH10. J. Biol. Chem. 2011, 286, 15666–15677. [CrossRef]
55. Tang, Z.; Li, C.; Kang, B.; Gao, G.; Li, C.; Zhang, Z. GEPIA: A web server for cancer and normal gene
expression profiling and interactive analyses. Nucleic Acids Res 2017, 45, W98–W102. [CrossRef]
56. Chandrashekar, D.S.; Bashel, B.; Balasubramanya, S.A.H.; Creighton, C.J.; Ponce-Rodriguez, I.;
Chakravarthi, B.; Varambally, S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and
Survival Analyses. Neoplasia 2017, 19, 649–658. [CrossRef]
57. Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.; Simonovic, M.; Roth, A.;
Santos, A.; Tsafou, K.P.; et al. STRING v10: Protein-protein interaction networks, integrated over the tree of
life. Nucleic Acids Res. 2015, 43, D447–D452. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
